180 related articles for article (PubMed ID: 14511464)
1. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification.
Read SB; Kulprathipanja NV; Gomez GG; Paul DB; Winston KR; Robbins JM; Kruse CA
J Interferon Cytokine Res; 2003 Jul; 23(7):379-93. PubMed ID: 14511464
[TBL] [Abstract][Full Text] [Related]
2. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
[TBL] [Abstract][Full Text] [Related]
3. Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Gomez GG; Kruse CA
J Immunother; 2007 Apr; 30(3):261-73. PubMed ID: 17414317
[TBL] [Abstract][Full Text] [Related]
4. Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.
Paul DB; Read SB; Kulprathipanja NV; Gomez GG; Kleinschmidt-DeMasters BK; Schiltz PM; Kruse CA
J Neurooncol; 2003; 64(1-2):89-99. PubMed ID: 12952290
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.
Nishihara K; Miyatake S; Sakata T; Yamashita J; Kikuchi H; Kawade Y; Zu Y; Namba Y; Hanaoka M; Watanabe Y
Cancer Res; 1988 Sep; 48(17):4730-5. PubMed ID: 3136912
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes.
Tajima K; Ito Y; Demachi A; Nishida K; Akatsuka Y; Tsujimura K; Hida T; Morishima Y; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Int J Cancer; 2004 Jun; 110(3):403-12. PubMed ID: 15095306
[TBL] [Abstract][Full Text] [Related]
7. Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability.
Takiguchi M; Ting JP; Buessow SC; Boyer C; Gillespie Y; Frelinger JA
Eur J Immunol; 1985 Aug; 15(8):809-14. PubMed ID: 2411569
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
9. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.
Wiendl H; Mitsdoerffer M; Hofmeister V; Wischhusen J; Bornemann A; Meyermann R; Weiss EH; Melms A; Weller M
J Immunol; 2002 May; 168(9):4772-80. PubMed ID: 11971028
[TBL] [Abstract][Full Text] [Related]
10. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.
Gomez GG; Varella-Garcia M; Kruse CA
Cancer Genet Cytogenet; 2006 Mar; 165(2):121-34. PubMed ID: 16527606
[TBL] [Abstract][Full Text] [Related]
11. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human IFN-gamma gene versus incubation with soluble IFN-gamma.
Nayak SK; Schiltz PM; Dillman RO
J Interferon Cytokine Res; 1999 Jan; 19(1):49-58. PubMed ID: 10048768
[TBL] [Abstract][Full Text] [Related]
12. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells.
Liu G; Yu JS; Zeng G; Yin D; Xie D; Black KL; Ying H
J Immunother; 2004; 27(3):220-6. PubMed ID: 15076139
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory role in gamma interferon production by a T cell growth factor-dependent experimental malignant glioma-specific cytotoxic T lymphocyte clone.
Yamasaki T; Handa H; Yamashita J; Watanabe Y; Taguchi M; Kuwata S; Namba Y; Hanaoka M
J Neurosurg; 1985 Nov; 63(5):763-70. PubMed ID: 3932609
[TBL] [Abstract][Full Text] [Related]
14. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
16. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
17. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
[TBL] [Abstract][Full Text] [Related]
18. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.
Akbasak A; Oldfield EH; Saris SC
J Neurosurg; 1991 Dec; 75(6):922-9. PubMed ID: 1941122
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.
Carrel S; Schmidt-Kessen A; Giuffrè L
Eur J Immunol; 1985 Feb; 15(2):118-23. PubMed ID: 3918869
[TBL] [Abstract][Full Text] [Related]
20. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
Zhang JG; Eguchi J; Kruse CA; Gomez GG; Fakhrai H; Schroter S; Ma W; Hoa N; Minev B; Delgado C; Wepsic HT; Okada H; Jadus MR
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):566-575. PubMed ID: 17255279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
